Browsed by
Tag: Selected

The New Home Company Reports Selected 2020 Third Quarter Preliminary Results

The New Home Company Reports Selected 2020 Third Quarter Preliminary Results

The New Home Company Inc. (NYSE: NWHM) today announced selected preliminary results for the 2020 third quarter. These estimated results are preliminary and unaudited.

Preliminary 2020 Third Quarter Financial Highlights (Estimated Results)

  • Net new orders of 251 as compared to 124 in the 2019 third quarter, a 102% increase

  • Monthly sales absorption of 3.5 per community as compared to 2.0 per community in the 2019 third quarter, a 75% increase

  • September net new orders of 99, a 106% increase compared to September 2019

  • Homes in backlog of 329 homes, representing $207.1 million in backlog value, as compared to 207 homes at the end of the 2019 third quarter, a 59% increase

  • Ending actively selling community count of 25, a 14% increase compared to the end of the 2019 third quarter

  • Homes sales revenue of $117.4 million as compared to $118.8 million for the 2019 third quarter

    • Deliveries of 157 as compared to 124 in the 2019 third quarter, a 27% increase

    • Average sales price of $748,000 as compared to $958,000 in the 2019 third quarter

  • Fee building revenues of $13.4 million as compared to $22.3 million for the 2019 third quarter

  • Cash and cash equivalents of $126.4 million as of September 30, 2020 as compared to $85.6 million as of June 30, 2020

  • Total debt, net of $290.3 million as compared to $327.4 million as of September 30, 2019

“The New Home Company continues to benefit from an incredibly strong housing market, as September’s order activity represented the highest monthly net order total in our company’s history driven by a monthly sales absorption rate of 4.0 per community,” said New Home Company CEO Leonard Miller. “Our preliminary results in the third quarter were also positively impacted by our ongoing shift to more affordable product, which helped push our monthly sales

Read the rest
Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020. The oral presentation will highlight new data from an ongoing open label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.

The details of the presentation are as follows:

  • Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata

  • Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time

  • Session: D1T03.3C: Late-Breaking News Session

  • Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The Company expects to begin Phase 3 evaluation of CTP-543 in the fourth quarter of 2020. Additional information on the upcoming trial is available on www.clinicaltrials.gov.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious

Read the rest
Vivera Pharmaceuticals Selected to Screen Travellers to the UAE for COVID-19

Vivera Pharmaceuticals Selected to Screen Travellers to the UAE for COVID-19

NEWPORT BEACH, Calif., Oct. 7, 2020 /PRNewswire/ — Vivera Pharmaceuticals has been selected by Pure Health, the largest laboratory network in the UAE, to test airline passengers flying into the United Arab Emirates in accordance with the UAE’s requirement for travelers to prove they are not infected with COVID-19. Pure Health has been appointed by the UAE’s government to launch this pioneering project to promote safe travel.

Vivera Pharmaceuticals, Inc. Logo (PRNewsfoto/Vivera Pharmaceuticals, Inc.)

Vivera Pharmaceuticals’ partners also offer concierge services for patient convenience.

“We are committed to supporting Pure Health in their efforts to control the COVID-19 pandemic and to assist in the facilitation of safe travel protocols for passengers flying into the UAE utilizing Vivera’s RT-PCR tests for COVID-19,” said Paul Edalat, CEO of Vivera Pharmaceuticals. “With our large network of provider partners, we are ideally placed to successfully deliver on this very important initiative and we are grateful for the trust placed in us by Pure Health.”

Partnered with CLIA-certified and CAP-accredited specimen collection and laboratory sites across Southern California, Vivera Pharmaceuticals’ partners also offer concierge services for patient convenience.

“Throughout the global pandemic, the UAE has entrusted Pure Health with safeguarding it from incoming COVID-19 threats. This responsibility requires us to ensure we only partner with verified and accredited facilities around the world, thus why we have partnered with Vivera Pharmaceuticals to make certain that the screening process is of the highest quality and to ensure an excellent customer service experience for the travelers,” said Pramodh B.N., Head of Commercial Operations at Pure Health.

UAE-issued regulations require all travelers flying into the UAE to provide proof of a negative COVID-19 test. Travelers without such a certificate are refused entry on to the flight.

The system is similar to the ESTA process in the United States. The traveler visits

Read the rest